Sign in or create an account to add this stock to your watchlist.
About Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600
Debt
Debt-to-Equity Ratio1.03
Current Ratio11.06
Quick Ratio11.06
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$161.63 million
Price / Sales52.39
Cash FlowN/A
Price / CashN/A
Book Value$4.05 per share
Price / Book23.26
Profitability
EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net Margins-45.56%
Return on Equity-29.67%
Return on Assets-13.46%
Miscellaneous
Employees400
Outstanding Shares89,900,000
Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions
What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
How were Neurocrine Biosciences' earnings last quarter?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings data on Monday, April, 30th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.18. The company had revenue of $71.08 million for the quarter, compared to analysts' expectations of $65.17 million. Neurocrine Biosciences had a negative net margin of 45.56% and a negative return on equity of 29.67%. During the same quarter in the previous year, the business posted ($0.90) EPS. View Neurocrine Biosciences' Earnings History.
When is Neurocrine Biosciences' next earnings date?
What price target have analysts set for NBIX?
13 brokerages have issued 12-month target prices for Neurocrine Biosciences' stock. Their forecasts range from $79.00 to $120.00. On average, they expect Neurocrine Biosciences' stock price to reach $102.7692 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.
Who are some of Neurocrine Biosciences' key competitors?
Some companies that are related to Neurocrine Biosciences include Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Momenta Pharmaceuticals (MNTA) and Denali Therapeutics (DNLI).
Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the folowing people:
- Dr. Kevin C. Gorman, CEO & Director (Age 60)
- Dr. Haig P. Bozigian, Chief Devel. Officer (Age 60)
- Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
- Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
- Mr. Matthew C. Abernethy, Chief Financial Officer (Age 38)
Has Neurocrine Biosciences been receiving favorable news coverage?
Media headlines about NBIX stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.11 on Accern's scale. They also gave press coverage about the company an impact score of 45.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Neurocrine Biosciences' major shareholders?
Neurocrine Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.46%), BB Biotech AG (3.79%), Franklin Resources Inc. (2.62%), Artisan Partners Limited Partnership (2.19%), Wells Fargo & Company MN (1.06%) and OppenheimerFunds Inc. (0.93%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.
Which major investors are selling Neurocrine Biosciences stock?
NBIX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Neuberger Berman Group LLC, Dupont Capital Management Corp, DekaBank Deutsche Girozentrale, A.R.T. Advisors LLC, BB Biotech AG and Candriam Luxembourg S.C.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.
Which major investors are buying Neurocrine Biosciences stock?
NBIX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Artisan Partners Limited Partnership, Victory Capital Management Inc., BlackRock Inc., Rock Springs Capital Management LP, Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc. and Columbus Circle Investors. View Insider Buying and Selling for Neurocrine Biosciences.
How do I buy shares of Neurocrine Biosciences?
Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurocrine Biosciences' stock price today?
One share of NBIX stock can currently be purchased for approximately $94.20.
How big of a company is Neurocrine Biosciences?
Neurocrine Biosciences has a market capitalization of $8.51 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.
How can I contact Neurocrine Biosciences?
Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]
MarketBeat Community Rating for Neurocrine Biosciences (NBIX)
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Neurocrine Biosciences in the last 12 months. Their average twelve-month price target is $102.7692, suggesting that the stock has a possible upside of 9.10%. The high price target for NBIX is $120.00 and the low price target for NBIX is $79.00. There are currently 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $102.7692 | $95.2308 | $91.50 | $78.8750 |
| Price Target Upside: | 9.10% upside | 24.13% upside | 7.12% upside | 5.67% upside |
Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History
Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Neurocrine Biosciences (NASDAQ:NBIX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.30%
Neurocrine Biosciences (NASDAQ NBIX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/7/2018 | Corinne H Nevinny | Director | Sell | 5,000 | $83.13 | $415,650.00 | 43,283 |  |
| 5/1/2018 | Kevin Charles Gorman | CEO | Sell | 126,832 | $80.75 | $10,241,684.00 | 473,865 | |
| 3/5/2018 | Haig P Bozigian | Insider | Sell | 75,873 | $90.00 | $6,828,570.00 | 18,041 | |
| 2/15/2018 | Gary A Lyons | Director | Sell | 5,000 | $84.67 | $423,350.00 | | |
| 2/12/2018 | Dimitri E Grigoriadis | Insider | Sell | 86,368 | $78.32 | $6,764,341.76 | 154,717 | |
| 2/9/2018 | Dimitri E Grigoriadis | Insider | Sell | 71,775 | $77.98 | $5,597,014.50 | 154,717 | |
| 2/6/2018 | Kevin Charles Gorman | CEO | Sell | 105,983 | $80.25 | $8,505,135.75 | 339,482 | |
| 2/5/2018 | Gary A Lyons | Director | Sell | 5,000 | $83.08 | $415,400.00 | 267,066 | |
| 2/5/2018 | Haig P Bozigian | Insider | Sell | 2,262 | $83.10 | $187,972.20 | 76,950 | |
| 1/24/2018 | William H Rastetter | Director | Sell | 9,500 | $90.00 | $855,000.00 | 34,250 | |
| 1/16/2018 | Haig P Bozigian | Insider | Sell | 1,625 | $79.12 | $128,570.00 | | |
| 1/16/2018 | Kevin Charles Gorman | CEO | Sell | 3,750 | $78.89 | $295,837.50 | | |
| 1/3/2018 | Darin Lippoldt | Insider | Sell | 1,979 | $79.36 | $157,053.44 | | |
| 12/28/2017 | Darin Lippoldt | Insider | Sell | 15,237 | $75.00 | $1,142,775.00 | | |
| 12/28/2017 | Darin Lippoldt | Insider | Sell | 15,237 | $75.00 | $1,142,775.00 | 28,394 | |
| 12/8/2017 | Darin Lippoldt | Insider | Sell | 2,955 | $75.00 | $221,625.00 | 16,112 | |
| 12/4/2017 | Darin Lippoldt | Insider | Sell | 6,279 | $75.04 | $471,176.16 | 19,436 | |
| 12/1/2017 | Gary A Lyons | Director | Sell | 10,000 | $72.92 | $729,200.00 | 272,066 | |
| 11/15/2017 | Darin Lippoldt | Insider | Sell | 9,900 | $73.05 | $723,195.00 | | |
| 11/8/2017 | Dimitri E Grigoriadis | Insider | Sell | 30,000 | $74.58 | $2,237,400.00 | 77,691 | |
| 11/2/2017 | Kyle Gano | Insider | Sell | 24,818 | $71.05 | $1,763,318.90 | 84,596 | |
| 10/2/2017 | Christopher Flint Obrien | Insider | Sell | 6,925 | $61.04 | $422,702.00 | 55,898 | |
| 9/6/2017 | Haig P Bozigian | Insider | Sell | 26,250 | $60.00 | $1,575,000.00 | 144,601 | |
| 9/5/2017 | Christopher Flint Obrien | Insider | Sell | 52,817 | $57.50 | $3,036,977.50 | 101,790 | |
| 8/9/2017 | Dimitri E Grigoriadis | Insider | Sell | 15,354 | $55.00 | $844,470.00 | 123,045 | |
| 8/4/2017 | Haig P Bozigian | Insider | Sell | 22,500 | $50.00 | $1,125,000.00 | 154,601 | |
| 7/27/2017 | Christopher Flint Obrien | Insider | Sell | 8,734 | $50.00 | $436,700.00 | 57,707 | |
| 5/23/2017 | Dimitri E Grigoriadis | Insider | Sell | 10,000 | $53.39 | $533,900.00 | 107,691 | |
| 5/19/2017 | Malcolm Lloyd-Smith | Insider | Sell | 9,960 | $53.63 | $534,154.80 | 17,997 | |
| 5/5/2017 | Corinne H Nevinny | Director | Sell | 5,000 | $53.98 | $269,900.00 | 34,603 | |
| 5/2/2017 | Dimitri E Grigoriadis | Insider | Sell | 10,000 | $55.00 | $550,000.00 | 117,691 | |
| 5/2/2017 | Kevin Charles Gorman | CEO | Sell | 21,739 | $53.23 | $1,157,166.97 | 354,346 | |
| 5/1/2017 | Kyle Gano | Insider | Sell | 15,000 | $54.00 | $810,000.00 | 88,246 | |
| 4/12/2017 | Haig P Bozigian | Insider | Sell | 13,065 | $50.42 | $658,737.30 | 129,805 | |
| 4/12/2017 | Kevin Charles Gorman | CEO | Sell | 19,596 | $50.42 | $988,030.32 | 332,913 | |
| 2/7/2017 | Malcolm Lloyd-Smith | Insider | Sell | 116 | $44.61 | $5,174.76 | | |
| 2/6/2017 | Dimitri E Grigoriadis | Insider | Sell | 727 | $43.13 | $31,355.51 | 115,756 | |
| 2/6/2017 | Kevin Charles Gorman | CEO | Sell | 3,010 | $43.18 | $129,971.80 | 250,542 | |
| 2/6/2017 | Timothy P Coughlin | CFO | Sell | 963 | $43.14 | $41,543.82 | 137,961 | |
| 2/3/2017 | Christopher Flint Obrien | Insider | Sell | 1,500 | $42.50 | $63,750.00 | 35,044 | |
| 2/3/2017 | Kevin Charles Gorman | CEO | Sell | 3,125 | $42.55 | $132,968.75 | 247,802 | |
| 2/1/2017 | William H Rastetter | Director | Sell | 10,750 | $42.28 | $454,510.00 | 25,000 | |
| 1/17/2017 | Haig P Bozigian | Insider | Sell | 1,625 | $40.63 | $66,023.75 | 114,704 | |
| 1/17/2017 | Kevin Charles Gorman | CEO | Sell | 3,750 | $40.65 | $152,437.50 | 244,677 | |
| 1/17/2017 | Timothy P Coughlin | CFO | Sell | 1,750 | $40.65 | $71,137.50 | 134,824 | |
| 1/10/2017 | Christopher Flint Obrien | Insider | Sell | 1,750 | $43.35 | $75,862.50 | 31,794 | |
| 1/10/2017 | Kevin Charles Gorman | CEO | Sell | 3,750 | $43.28 | $162,300.00 | 240,927 | |
| 11/15/2016 | Christopher Flint Obrien | Insider | Sell | 25,000 | $52.84 | $1,321,000.00 | 30,044 | |
| 9/1/2016 | Malcolm Lloyd-Smith | Insider | Sell | 9,000 | $50.00 | $450,000.00 | 9,000 | |
| 8/15/2016 | Christopher Flint Obrien | Insider | Sell | 12,500 | $48.73 | $609,125.00 | 55,044 | |
| 8/8/2016 | Corinne H Nevinny | Director | Sell | 5,000 | $48.54 | $242,700.00 | 25,555 | |
| 5/25/2016 | Richard F Pops | Director | Sell | 15,000 | $46.72 | $700,800.00 | 15,464 | |
| 5/16/2016 | Christopher Flint Obrien | Insider | Sell | 25,000 | $45.00 | $1,125,000.00 | 80,044 | |
| 4/11/2016 | Kyle Gano | Insider | Sell | 41,770 | $44.02 | $1,838,715.40 | 57,788 | |
| 4/6/2016 | Christopher Flint Obrien | Insider | Sell | 25,000 | $45.00 | $1,125,000.00 | 105,044 | |
| 2/3/2016 | Haig P Bozigian | Insider | Sell | 1,375 | $38.13 | $52,428.75 | 111,454 | |
| 2/3/2016 | Kevin Charles Gorman | CEO | Sell | 3,125 | $38.04 | $118,875.00 | 228,077 | |
| 2/3/2016 | Timothy P Coughlin | CFO | Sell | 1,500 | $38.06 | $57,090.00 | 131,374 | |
| 1/19/2016 | Haig P Bozigian | Insider | Sell | 1,625 | $46.77 | $76,001.25 | 110,079 | |
| 1/19/2016 | Kevin Charles Gorman | CEO | Sell | 3,750 | $46.70 | $175,125.00 | 224,952 | |
| 1/19/2016 | Timothy P Coughlin | CFO | Sell | 1,750 | $46.69 | $81,707.50 | 129,874 | |
| 1/11/2016 | Haig P Bozigian | Insider | Sell | 1,625 | $44.25 | $71,906.25 | 108,454 | |
| 1/11/2016 | Kevin Charles Gorman | CEO | Sell | 3,750 | $44.17 | $165,637.50 | 221,202 | |
| 1/11/2016 | Timothy P Coughlin | CFO | Sell | 1,750 | $44.25 | $77,437.50 | 128,124 | |
| 11/27/2015 | Dimitri E. Grigoriadis | insider | Sell | 10,000 | $57.50 | $575,000.00 | 105,308 | |
| 11/9/2015 | Darin Lippoldt | insider | Sell | 23,761 | $52.92 | $1,257,432.12 | | |
| 10/16/2015 | Haig P Bozigian | Insider | Sell | 25,000 | $47.78 | $1,194,500.00 | 106,829 | |
| 10/16/2015 | Kevin Charles Gorman | CEO | Sell | 33,500 | $47.77 | $1,600,295.00 | 217,452 | |
| 9/18/2015 | Gary A. Lyons | Director | Sell | 15,000 | $54.89 | $823,350.00 | 252,066 | |
| 7/20/2015 | Dimitri E Grigoriadis | Insider | Sell | 19,646 | $55.00 | $1,080,530.00 | | |
| 7/20/2015 | Timothy P Coughlin | CFO | Sell | 20,000 | $55.00 | $1,100,000.00 | | |
| 7/13/2015 | Dimitri E Grigoriadis | Insider | Sell | 10,000 | $50.00 | $500,000.00 | | |
| 7/13/2015 | Timothy P Coughlin | CFO | Sell | 20,000 | $50.00 | $1,000,000.00 | | |
| 6/23/2015 | W Thomas Mitchell | Director | Sell | 15,000 | $49.35 | $740,250.00 | | |
| 6/8/2015 | Christopher Flint Obrien | Insider | Sell | 10,000 | $45.00 | $450,000.00 | | |
| 6/8/2015 | Timothy P Coughlin | CFO | Sell | 60,000 | $45.08 | $2,704,800.00 | | |
| 3/24/2015 | Gary A Lyons | Director | Sell | 30,000 | $41.53 | $1,245,900.00 | | |
| 3/24/2015 | Kevin Charles Gorman | CEO | Sell | 40,000 | $41.53 | $1,661,200.00 | | |
| 2/10/2015 | Dimitri E Grigoriadis | Insider | Sell | 20,000 | $35.00 | $700,000.00 | | |
| 1/16/2015 | Christopher Flint Obrien | Insider | Sell | 1,750 | $30.79 | $53,882.50 | | |
| 1/16/2015 | Kevin Charles Gorman | CEO | Sell | 3,750 | $30.79 | $115,462.50 | | |
| 1/12/2015 | Kevin Charles Gorman | CEO | Sell | 3,750 | $28.43 | $106,612.50 | | |
| 1/12/2015 | Kyle Gano | Insider | Sell | 1,250 | $28.41 | $35,512.50 | | |
| 1/12/2015 | Timothy P Coughlin | CFO | Sell | 1,750 | $28.37 | $49,647.50 | | |
| 1/8/2015 | Dimitri E Grigoriadis | Insider | Sell | 30,000 | $27.35 | $820,500.00 | | |
| 1/8/2015 | Kevin Charles Gorman | CEO | Sell | 25,000 | $27.39 | $684,750.00 | | |
| 1/8/2015 | Timothy P Coughlin | CFO | Sell | 10,000 | $27.25 | $272,500.00 | | |
| 1/5/2015 | Dimitri E Grigoriadis | Insider | Sell | 2,500 | $22.76 | $56,900.00 | | |
| 1/2/2015 | W Thomas Mitchell | Director | Sell | 8,000 | $22.79 | $182,320.00 | | |
| 12/19/2014 | Christopher Flint Obrien | Insider | Sell | 20,000 | $24.02 | $480,400.00 | | |
| 12/19/2014 | Kevin Charles Gorman | CEO | Sell | 70,000 | $23.41 | $1,638,700.00 | | |
| 12/19/2014 | Timothy P Coughlin | CFO | Sell | 30,000 | $23.46 | $703,800.00 | | |
| 12/17/2014 | Kyle Gano | Insider | Sell | 4,957 | $22.50 | $111,532.50 | | |
| 12/15/2014 | Dimitri E Grigoriadis | Insider | Sell | 12,794 | $22.35 | $285,945.90 | | |
| 12/12/2014 | Kyle Gano | Insider | Sell | 4,043 | $22.50 | $90,967.50 | | |
| 12/11/2014 | Christopher Flint Obrien | Insider | Sell | 40,000 | $21.82 | $872,800.00 | | |
| 12/10/2014 | Timothy P Coughlin | CFO | Sell | 20,000 | $21.48 | $429,600.00 | | |
| 12/10/2014 | W Thomas Mitchell | Director | Sell | 7,000 | $21.90 | $153,300.00 | | |
| 11/28/2014 | Timothy P Coughlin | CFO | Sell | 10,000 | $20.14 | $201,400.00 | | |
| 11/24/2014 | Christopher Flint Obrien | Insider | Sell | 5,463 | $19.53 | $106,692.39 | | |
| 10/31/2014 | Timothy P Coughlin | CFO | Sell | 10,000 | $19.00 | $190,000.00 | | |
| 10/30/2014 | Timothy P Coughlin | CFO | Sell | 20,000 | $18.31 | $366,200.00 | | |
| 10/1/2014 | W Thomas Mitchell | Director | Sell | 1,275 | $15.50 | $19,762.50 | | |
| 9/15/2014 | Gary A Lyons | Director | Sell | 20,000 | $15.66 | $313,200.00 | | |
| 1/17/2014 | Dimitri Grigoriadis | Insider | Sell | 25,000 | $20.00 | $500,000.00 | 77,058 | |
| 1/10/2014 | Christopher Flint Obrien | Insider | Sell | 6,750 | $18.88 | $127,440.00 | 96,544 | |
| 1/10/2014 | Kevin Charles Gorman | CEO | Sell | 3,750 | $18.57 | $69,637.50 | 180,952 | |
| 1/10/2014 | Timothy Coughlin | CFO | Sell | 1,750 | $18.56 | $32,480.00 | 97,874 | |
| 1/7/2014 | Dimitri Grigoriadis | Insider | Sell | 25,000 | $17.50 | $437,500.00 | 75,433 | |
| 1/7/2014 | Kevin Charles Gorman | CEO | Sell | 108,000 | $16.76 | $1,810,080.00 | 177,202 | |
| 1/7/2014 | Timothy Coughlin | CFO | Sell | 70,000 | $16.75 | $1,172,500.00 | 96,124 | |
| 9/4/2013 | Kyle Gano | Insider | Sell | 2,400 | $15.61 | $37,464.00 | 22,488 | |
| 9/3/2013 | Christopher Flint Obrien | Insider | Sell | 5,000 | $16.00 | $80,000.00 | 94,794 | |
| 8/21/2013 | Haig Bozigian | Insider | Sell | 13,999 | $15.04 | $210,544.96 | 76,954 | |
| 8/21/2013 | Timothy Coughlin | CFO | Sell | 19,035 | $15.05 | $286,476.75 | 96,124 | |
| 8/6/2013 | W Thomas Mitchell | Director | Sell | 1,531 | $14.70 | $22,505.70 | 1,000 | |
| 8/5/2013 | Haig Bozigian | Insider | Sell | 11,001 | $15.00 | $165,015.00 | 76,954 | |
| 8/5/2013 | Timothy Coughlin | CFO | Sell | 10,965 | $14.99 | $164,365.35 | 96,124 | |
| 7/12/2013 | Christopher Flint Obrien | Insider | Sell | 5,000 | $14.50 | $72,500.00 | | |
| 6/28/2013 | Christopher Flint Obrien | Insider | Sell | 11,357 | $13.33 | $151,388.81 | | |
| 6/27/2013 | Haig P Bozigian | Insider | Sell | 8,000 | $13.00 | $104,000.00 | | |
| 6/21/2013 | Dimitri E Grigoriadis | Insider | Sell | 46,837 | $12.51 | $585,930.87 | | |
(Data available from 1/1/2013 forward)
Neurocrine Biosciences (NASDAQ NBIX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $86.98 Million
www.americanbankingnews.com - May 22 at 4:16 AM |
| Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - May 20 at 9:37 AM |
| Neurocrine Biosciences (NBIX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 20 at 1:34 AM |
| Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to Strong-Buy
www.americanbankingnews.com - May 18 at 1:19 PM |
| FY2021 EPS Estimates for Neurocrine Biosciences Lifted by Oppenheimer (NBIX)
www.americanbankingnews.com - May 17 at 9:10 AM |
| Neurocrine Biosciences (NBIX) Raised to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 15 at 11:34 AM |
| Oppenheimer Analysts Give Neurocrine Biosciences (NBIX) a $120.00 Price Target
www.americanbankingnews.com - May 14 at 12:42 PM |
 | Noteworthy Friday Option Activity: NBIX, VZ, JELD
www.nasdaq.com - May 11 at 5:23 PM |
| Neurocrine Biosciences (NBIX) Director Corinne H. Nevinny Sells 5,000 Shares
www.americanbankingnews.com - May 9 at 7:53 PM |
 | Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 9 at 5:09 PM |
| Neurocrine Biosciences (NBIX) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - May 9 at 10:36 AM |
| Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
finance.yahoo.com - May 8 at 5:10 PM |
| Neurocrine Biosciences (NBIX) Rating Reiterated by Cowen
www.americanbankingnews.com - May 7 at 9:30 PM |
 | 5 Stocks That Are Screaming Buys Right Now
www.thestreet.com - May 7 at 5:15 PM |
| Neurocrine Biosciences (NBIX) to Post Q2 2018 Earnings of ($0.17) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 7 at 1:56 AM |
 | Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real ...
www.prnewswire.com - May 4 at 8:41 AM |
| Brokerages Expect Neurocrine Biosciences (NBIX) Will Post Quarterly Sales of $81.22 Million
www.americanbankingnews.com - May 4 at 2:10 AM |
| Kevin Charles Gorman Sells 126,832 Shares of Neurocrine Biosciences (NBIX) Stock
www.americanbankingnews.com - May 3 at 10:18 PM |
| NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth
finance.yahoo.com - May 3 at 5:02 PM |
| Equities Analysts Offer Predictions for Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - May 3 at 8:16 AM |
| Oppenheimer Weighs in on Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - May 3 at 8:16 AM |
| Zacks: Analysts Expect Neurocrine Biosciences (NBIX) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 2 at 9:58 PM |
| Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
finance.yahoo.com - May 2 at 5:12 PM |
| Oppenheimer Brokers Cut Earnings Estimates for Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - May 2 at 10:00 AM |
| FY2019 Earnings Estimate for Neurocrine Biosciences Issued By Jefferies Group (NBIX)
www.americanbankingnews.com - May 2 at 10:00 AM |
| Bank of America Increases Neurocrine Biosciences (NBIX) Price Target to $102.00
www.americanbankingnews.com - May 1 at 2:38 PM |
| Neurocrine Biosciences (NBIX) Given a $99.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - May 1 at 1:28 PM |
| JPMorgan Chase Increases Neurocrine Biosciences (NBIX) Price Target to $103.00
www.americanbankingnews.com - May 1 at 10:42 AM |
| Neurocrine Biosciences (NBIX) Receives Outperform Rating from Robert W. Baird
www.americanbankingnews.com - May 1 at 9:40 AM |
 | Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 1 at 8:50 AM |
| Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT
finance.yahoo.com - May 1 at 8:50 AM |
| Neurocrine Biosciences (NBIX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS
www.americanbankingnews.com - May 1 at 8:31 AM |
| Neurocrine Biosciences misses by $0.16, beats on revenue
seekingalpha.com - April 30 at 4:56 PM |
| Neurocrine: 1Q Earnings Snapshot
finance.yahoo.com - April 30 at 4:56 PM |
| Neurocrine Biosciences Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 30 at 4:56 PM |
| Neurocrine Biosciences (NBIX) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 4:29 AM |
| AbbVie Presents New Investigational Data For Elagolix
www.nasdaq.com - April 27 at 9:02 AM |
 | Neurocrine Biosciences (NBIX) Highlights New Data Analyses Demonstrating INGREZZA Improved Tardive Dyskinesia ...
www.streetinsider.com - April 26 at 5:00 PM |
| How Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
finance.yahoo.com - April 26 at 5:00 PM |
| Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
www.prnewswire.com - April 25 at 8:31 PM |
| Neurocrine Biosciences (NBIX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 25 at 1:34 AM |
| Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results
finance.yahoo.com - April 23 at 4:56 PM |
| Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ...
www.prnewswire.com - April 19 at 5:15 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ...
www.prnewswire.com - April 19 at 5:15 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 19 at 8:42 AM |
| Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
finance.yahoo.com - April 18 at 5:22 PM |
| Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million
www.americanbankingnews.com - April 17 at 2:33 AM |
| Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per Share
www.americanbankingnews.com - April 15 at 7:17 PM |
| Oppenheimer Comments on Neurocrine Biosciences' Q2 2018 Earnings (NBIX)
www.americanbankingnews.com - April 13 at 8:51 AM |
| Ingrezza: Boosting Neurocrine’s Top Line
finance.yahoo.com - April 12 at 5:10 PM |
Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement
Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Saturday, May, 26, 2018
Loading chart…
